STOCK TITAN

ANRO - ANRO STOCK NEWS

Welcome to our dedicated news page for ANRO (Ticker: ANRO), a resource for investors and traders seeking the latest updates and insights on ANRO.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ANRO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ANRO's position in the market.

Rhea-AI Summary
Alto Neuroscience, Inc. (ANRO) closed its upsized initial public offering of 9,246,000 shares of common stock, raising approximately $147.9 million. The offering price was $16.00 per share, with underwriters exercising their option to purchase 1,206,000 additional shares. Alto's common stock is listed on the NYSE under the ticker symbol ANRO. Jefferies, TD Cowen, Stifel, and William Blair were the joint book-running managers for the offering, while Baird acted as the lead manager. Registration statements were filed with the SEC and became effective on February 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
IPO offering
-
Rhea-AI Summary
Alto Neuroscience, Inc. (NYSE: ANRO) has announced the pricing of its upsized initial public offering of 8,040,000 shares of common stock at a public offering price of $16.00 per share. The aggregate gross proceeds are expected to be approximately $128.6 million before deducting underwriting discounts and commissions. The company has also granted the underwriters a 30-day option to purchase up to an additional 1,206,000 shares of common stock at the initial public offering price. The offering is expected to close on February 6, 2024, subject to customary closing conditions. Jefferies, TD Cowen, Stifel, and William Blair are acting as joint book-running managers for the offering, with Baird as the lead manager. The shares are expected to begin trading on the New York Stock Exchange on February 2, 2024 under the ticker symbol 'ANRO'.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
IPO offering
ANRO

NYSE:ANRO

ANRO Rankings

ANRO Stock Data